Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Cystic Fibrosis Drug Sales Should Soar; VX-661/Ivacaftor To Lead Way

Executive Summary

Sales of key cystic fibrosis drugs will jump in western economies over the next decade, driven by strong uptake of high-cost CFTR modulator therapies and longer use as life expectancies improve, according to a new report by Datamonitor Healthcare.

Advertisement

Related Content

Keeping Track: Submissions For Dupilumab, Nusinersen; AbbVie Finds Breakthrough Space In Hep C
Vertex's VX-661 Has Positive Outlook Despite Futility Finding
Why Pricing Orkambi Below Kalydeco Is A Savvy Strategy For Vertex
Vertex’s Orkambi Approved With Broad Label For Cystic Fibrosis
Vertex Gets Quick FDA Approval Of Kalydeco; Prices New CF Drug At $294,000 Per Year

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register